## Edgar Filing: Esperion Therapeutics, Inc. - Form 4

Esperion Therap	peutics, Inc.									
Form 4 March 20, 2015										
								OMB A	PPROVAL	
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549								OMB Number:	3235-0287	
Check this box if no longer subject to Section 16. Form 4 or Form 5 Filed pursuant to Section 16(a) of the Securities Exchange Act of 193							Expires:	January 31, 2005		
								Estimated burden hou	Estimated average burden hours per response 0.5	
obligations may continue <i>See</i> Instruction 1(b).	e. Section 17	(a) of the l	Public U	Jtility Hol	lding Coi		of 1935 or Section	on		
(Print or Type Resp	oonses)									
1. Name and Addr Lalwani Naren	2. Issuer Name <b>and</b> Ticker or Trading Symbol				5. Relationship of Reporting Person(s) to Issuer					
			Esperie	on Therap	eutics, Ir	nc. [ESPR]	R] (Check all applicable)			
(Last) C/O ESPERIO	3. Date of Earliest Transaction (Month/Day/Year) 03/18/2015				Director 10% Owner X Officer (give title Other (specify					
INC., 3891 RA SUITE 150	NCHERO DI	RIVE,					below) Chief	below) Operating Officient	cer	
				endment, D onth/Day/Yea	-	al	6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person			
ANN ARBOR,	, MI 48108						Form filed by Person	More than One R	eporting	
(City)	(State)	(Zip)	Tab	ole I - Non-	Derivative	Securities A	cquired, Disposed o	of, or Beneficia	lly Owned	
	Transaction Date onth/Day/Year)	2A. Deem Execution any (Month/Da	Date, if	Code (Instr. 8)	4. Securit onAcquired Disposed (Instr. 3, -	(A) or of (D)	Securities Beneficially Owned	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
Densin dem Densert		. f h . 1	<b>f</b>		£					
Reminder: Report	on a separate line	e for each cl	ass of sec	urities bene	Perso inforr requi	ons who res nation cont red to resp ays a curre	or indirectly. spond to the colle- ained in this form ond unless the for ntly valid OMB co	are not rm	SEC 1474 (9-02)	
	Tab					sposed of, or convertible :	Beneficially Owned securities)	I		

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number of	6. Date Exercisable and	7. Title and Amount of	f 8
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transacti	orDerivative	Expiration Date	Underlying Securities	D

1

## Edgar Filing: Esperion Therapeutics, Inc. - Form 4

Security (Instr. 3)	-		ny Month/Day/Yea			Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		(Month/Day/Year)		(Instr. 3 and 4)	
				Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Stock option (right to buy)	\$ 105.72	03/18/2015		А	20,000		<u>(1)</u>	03/18/2025	Common Stock	20,000	
Reporting Owners											
Reporting Owner Name / Address			Relationships								
		Director	10% Owner	Officer			Other				
Lalwani Narendra D. C/O ESPERION THERAPEUTICS, INC. 3891 RANCHERO DRIVE, SUITE 150 ANN ARBOR, MI 48108				Chief Operating Officer							
Signa	tures										
/s/ Richa attorney	rd B. Bartram	a, by power of	03.	/20/2015							
*•	Signature of Repo	rting Person		Date							

## **Explanation of Responses:**

\* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) 25% of option vests on March 18, 2016 and the remainder shall vest in equal quarterly installments over a three (3) year period thereafter.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

S (.